PHENYLKETONURICS: CHOLESTYRAMINE for ORAL SUSPENSION USP, LIGHT
CONTAINS 14.0 mg PHENYLALANINE PER 5 GRAM DOSE.
Chronic use of QUESTRAN may be associated with increased bleeding tendency due to
hypoprothrombinemia associated with Vitamin K deficiency. This will usually respond promptly to
parenteral Vitamin K1 and recurrences can be prevented by oral administration of Vitamin K1. Reduction
of serum or red cell folate has been reported over long term administration of QUESTRAN.
Supplementation with folic acid should be considered in these cases.
There is a possibility that prolonged use of QUESTRAN, since it is a chloride form of anion exchange
resin, may produce hyperchloremic acidosis. This would especially be true in younger and smaller
patients where the relative dosage may be higher. Caution should also be exercised in patients with
renal insufficiency or volume depletion, and in patients receiving concomitant spironolactone.
QUESTRAN may produce or worsen pre-existing constipation. The dosage should be increased
gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-existing
constipation, the starting dose should be 1 packet or 1 scoop once daily for 5–7 days, increasing to
twice daily with monitoring of constipation and of serum lipoproteins, at least twice, 4–6 weeks apart.
Increased fluid intake and fiber intake should be encouraged to alleviate constipation and a stool
softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased
as needed by one dose/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If
constipation worsens or the desired therapeutic response is not achieved at one to six doses/day,
combination therapy or alternate therapy should be considered. Particular effort should be made to
avoid constipation in patients with symptomatic coronary artery disease. Constipation associated with
QUESTRAN may aggravate hemorrhoids.
Serum cholesterol levels should be determined frequently during the first few months of therapy and
periodically thereafter. Serum triglyceride levels should be measured periodically to detect whether
significant changes have occurred.
The LRC-CPPT showed a dose-related increase in serum triglycerides of 10.7%–17.1% in the
cholestyramine-treated group, compared with an increase of 7.9%–11.7% in the placebo group. Based
on the mean values and adjusting for the placebo group, the cholestyramine-treated group showed an
increase of 5% over pre-entry levels the first year of the study and an increase of 4.3% the seventh
Carcinogenesis And Mutagenesis And Impairment Of Fertility
In studies conducted in rats in which cholestyramine resin was used as a tool to investigate the role of
various intestinal factors, such as fat, bile salts and microbial flora, in the development of intestinal
tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in
cholestyramine resin-treated rats than in control rats.
The relevance of this laboratory observation from studies in rats to the clinical use of QUESTRAN is
not known. In the LRC-CPPT study referred to above, the total incidence of fatal and nonfatal neoplasms
was similar in both treatment groups. When the many different categories of tumors are examined,
various alimentary system cancers were somewhat more prevalent in the cholestyramine group. The
small numbers and the multiple categories prevent conclusions from being drawn. However, in view of
the fact that cholestyramine resin is confined to the GI tract and not absorbed, and in light of the animal
experiments referred to above, a six-year post-trial follow-up of the LRC-CPPT5 patient population
has been completed (a total of 13.4 years of in-trial plus post-trial follow-up) and revealed no
significant difference in the incidence of cause-specific mortality or cancer morbidity between
cholestyramine and placebo treated patients.
Pregnancy Category C
There are no adequate and well controlled studies in pregnant women. The use of QUESTRAN in
pregnancy or lactation or by women of childbearing age requires that the potential benefits of drug
therapy be weighed against the possible hazards to the mother and child. QUESTRAN is not absorbed
systemically, however, it is known to interfere with absorption of fat-soluble vitamins; accordingly,
regular prenatal supplementation may not be adequate (see DRUG INTERACTIONS).
Caution should be exercised when QUESTRAN is administered to a nursing mother. The possible lack
of proper vitamin absorption described in the “Pregnancy” section
Although an optimal dosage schedule has not been established, standard texts(6,7) list a usual pediatric
dose of 240 mg/kg/day of anhydrous cholestyramine resin in two to three divided doses, normally not to
exceed 8 gm/day with dose titration based on response and tolerance.
In calculating pediatric dosages, 44.4 mg of anhydrous choleystramine resin are contained in 100 mg of
QUESTRAN powder and 80 mg of anhydrous cholestyramine resin are contained in 100 mg of
The effects of long-term administration, as well as its effect in maintaining lowered cholesterol levels
in pediatric patients, are unknown. (Also see ADVERSE REACTIONS.)
The Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary
Prevention Trial: Results of 6 Years of Post-Trial Follow-up. Arch Intern Med 1992; 152:1399-
Behrman RE et al (eds): Nelson, Textbook of Pediatrics, ed 15. Philadelphia, PA, WB Saunders
Takemoto CK et al (eds): Pediatric Dosage Handbook, ed 3. Cleveland/Akron, OH, Lexi-Comp,